The field of AAV-based gene therapies is rapidly evolving. This applies to aspects such as manufacturing, analytics and regulations which are core competencies of IDT Biologika, a full-service CDMO specialized in virus-based therapies and vaccines.

In the following, we present insights into our cross-serotype, robust high-yield AAV manufacturing platform. The platform was established with the objective of providing short timelines and a cost-effective scalable process to produce clinical trial and commercial material in up to 2000-liter bioreactors. Current and future areas of process and analytical development are outlined in this presentation.